Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure

Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure - RECOQS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012604

Enrollment

Registered

2013-12-17

Start date

2013-06-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

Ubiquinol 200mg twice daily, 12 weeks, followed by placebo 12 weeks Placebo 12 weeks, followed by Ubiquinol 200mg twice daily, 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic heart failure patients whose left ventricular ejection fraction are less than 40 %.

Exclusion criteria

Exclusion criteria: Malignancy, severe infection, severe trauma, hemodialysis.

Design outcomes

Primary

Measure	Time frame
Changes in endothelial function assessed by EndoPAT 2000 between before and after intervention.	—

Secondary

Measure	Time frame
Changes in functional capacity, left ventricular function, oxydative stress marker, inflammation marker, and COQ10 concentration in peripheral blood.	—

Countries

Japan

Contacts

Public ContactMasaaki Konishi

Yokohama City University Medical Center Division of Cardiology

m_koni@yokohama-cu.ac.jp045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026